132 related articles for article (PubMed ID: 30305476)
1. Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy.
Matsukawa T; Suto K; Miyoshi H; Oshimi K; Ohshima K; Miyagishima T
J Clin Exp Hematop; 2018 Dec; 58(4):184-187. PubMed ID: 30305476
[No Abstract] [Full Text] [Related]
2. ESHAP therapy effective in a patient with Langerhans cell sarcoma.
Yoshimi A; Kumano K; Motokura T; Takazawa Y; Oota S; Chiba S; Takahashi T; Fukayama M; Kurokawa M
Int J Hematol; 2008 Jun; 87(5):532-537. PubMed ID: 18415657
[TBL] [Abstract][Full Text] [Related]
3. Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib.
Mourah S; Lorillon G; Meignin V; Vercellino L; de Margerie-Mellon C; Pages C; Goldwirt L; How-Kit A; Tost J; Lebbe C; Tazi A
Blood; 2015 Dec; 126(24):2649-52. PubMed ID: 26468227
[No Abstract] [Full Text] [Related]
4. Leukaemic presentation of angioimmunoblastic T-cell lymphoma.
Lin KW; Lee YS; Phipps C
Br J Haematol; 2014 Sep; 166(6):808. PubMed ID: 24974735
[No Abstract] [Full Text] [Related]
5. Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate.
Sato S; Tanaka E; Tamai Y
Ann Hematol; 2019 Mar; 98(3):801-803. PubMed ID: 30652209
[No Abstract] [Full Text] [Related]
6. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Isogai R; Fukao M; Kawada A
J Dermatol; 2007 Aug; 34(8):556-60. PubMed ID: 17683387
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Langerhans cell sarcoma relapsing systemically: Complete remission with the EPIG regimen.
Kwong YL
Ann Hematol; 2015 Apr; 94(4):697-9. PubMed ID: 25186787
[No Abstract] [Full Text] [Related]
8. Langerhans cell sarcoma emanating from the upper arm skin: successful treatment by MAID regimen.
Uchida K; Kobayashi S; Inukai T; Noriki S; Imamura Y; Nakajima H; Yayama T; Orwotho N; Baba H
J Orthop Sci; 2008 Jan; 13(1):89-93. PubMed ID: 18274862
[No Abstract] [Full Text] [Related]
9. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
10. Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy.
Isogai R; Kawada A; Hashimoto K; Aragane Y; Tezuka T; Maeda Y; Kanamaru A
Dermatology; 2004; 209(3):243-5. PubMed ID: 15459544
[No Abstract] [Full Text] [Related]
11. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma.
Lamar ZS; Fino N; Palmer J; Gruber L; Morris BB; Raetskaya-Solntseva O; Kennedy L; Vaidya R; Hurd D; Zamkoff K
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):76-81. PubMed ID: 26725264
[TBL] [Abstract][Full Text] [Related]
12. Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.
Floeter AE; Patel A; Tran M; Chamberlain MC; Hendrie PC; Gopal AK; Cassaday RD
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):225-230. PubMed ID: 28169156
[TBL] [Abstract][Full Text] [Related]
13. Making moves: Transitioning R-EPOCH to the ambulatory setting.
Martin AL; Frank JP; Waggoner ML
J Oncol Pharm Pract; 2018 Dec; 24(8):617-622. PubMed ID: 28782408
[TBL] [Abstract][Full Text] [Related]
14. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
15. A case of an adult Langerhans cell sarcoma.
Ma X; Li W; Du J; Cai L; Zhang J
Int J Dermatol; 2016 Jan; 55(1):92-6. PubMed ID: 25312302
[No Abstract] [Full Text] [Related]
16. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience.
Huang H; Lin Z; Lin X; Cai Q; Xia Z; Jiang W
Leuk Lymphoma; 2011 Jun; 52(6):1041-8. PubMed ID: 21599590
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous involvement in systemic anaplastic large cell lymphoma.
Kwok C; Salmo E
J Dtsch Dermatol Ges; 2015 Jul; 13(7):693-5. PubMed ID: 26031654
[No Abstract] [Full Text] [Related]
19. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
Wilson WH; Jamis-Dow C; Bryant G; Balis FM; Klecker RW; Bates SE; Chabner BA; Steinberg SM; Kohler DR; Wittes RE
J Clin Oncol; 1995 Aug; 13(8):1985-94. PubMed ID: 7636539
[TBL] [Abstract][Full Text] [Related]
20. Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Aurer I; Bašić-Kinda S; Radman I; Ilić I; Grah JJ
Ann Hematol; 2014 Jan; 93(1):177-8. PubMed ID: 23636314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
